Cargando…

Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer

Liver cancer is one of the leading causes of death worldwide due to late diagnosis and scarcity of treatment options. The major risk factor for liver cancer is cirrhosis with the underlying causes of cirrhosis being viral infection (hepatitis B or C), metabolic deregulation (Non-alcoholic fatty live...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaffe, Eleanna, Magkrioti, Christiana, Aidinis, Vassilis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893780/
https://www.ncbi.nlm.nih.gov/pubmed/31652837
http://dx.doi.org/10.3390/cancers11111626
_version_ 1783476279080648704
author Kaffe, Eleanna
Magkrioti, Christiana
Aidinis, Vassilis
author_facet Kaffe, Eleanna
Magkrioti, Christiana
Aidinis, Vassilis
author_sort Kaffe, Eleanna
collection PubMed
description Liver cancer is one of the leading causes of death worldwide due to late diagnosis and scarcity of treatment options. The major risk factor for liver cancer is cirrhosis with the underlying causes of cirrhosis being viral infection (hepatitis B or C), metabolic deregulation (Non-alcoholic fatty liver disease (NAFLD) in the presence of obesity and diabetes), alcohol or cholestatic disorders. Lysophosphatidic acid (LPA) is a bioactive phospholipid with numerous effects, most of them compatible with the hallmarks of cancer (proliferation, migration, invasion, survival, evasion of apoptosis, deregulated metabolism, neoangiogenesis, etc.). Autotaxin (ATX) is the enzyme responsible for the bulk of extracellular LPA production, and together with LPA signaling is involved in chronic inflammatory diseases, fibrosis and cancer. This review discusses the most important findings and the mechanisms related to ATX/LPA/LPAR involvement on metabolic, viral and cholestatic liver disorders and their progression to liver cancer in the context of human patients and mouse models. It focuses on the role of ATX/LPA in NAFLD development and its progression to liver cancer as NAFLD has an increasing incidence which is associated with the increasing incidence of liver cancer. Bearing in mind that adipose tissue accounts for the largest amount of LPA production, many studies have implicated LPA in adipose tissue metabolism and inflammation, liver steatosis, insulin resistance, glucose intolerance and lipogenesis. At the same time, LPA and ATX play crucial roles in fibrotic diseases. Given that hepatocellular carcinoma (HCC) is usually developed on the background of liver fibrosis, therapies that both delay the progression of fibrosis and prevent its development to malignancy would be very promising. Therefore, ATX/LPA signaling appears as an attractive therapeutic target as evidenced by the fact that it is involved in both liver fibrosis progression and liver cancer development.
format Online
Article
Text
id pubmed-6893780
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68937802019-12-23 Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer Kaffe, Eleanna Magkrioti, Christiana Aidinis, Vassilis Cancers (Basel) Review Liver cancer is one of the leading causes of death worldwide due to late diagnosis and scarcity of treatment options. The major risk factor for liver cancer is cirrhosis with the underlying causes of cirrhosis being viral infection (hepatitis B or C), metabolic deregulation (Non-alcoholic fatty liver disease (NAFLD) in the presence of obesity and diabetes), alcohol or cholestatic disorders. Lysophosphatidic acid (LPA) is a bioactive phospholipid with numerous effects, most of them compatible with the hallmarks of cancer (proliferation, migration, invasion, survival, evasion of apoptosis, deregulated metabolism, neoangiogenesis, etc.). Autotaxin (ATX) is the enzyme responsible for the bulk of extracellular LPA production, and together with LPA signaling is involved in chronic inflammatory diseases, fibrosis and cancer. This review discusses the most important findings and the mechanisms related to ATX/LPA/LPAR involvement on metabolic, viral and cholestatic liver disorders and their progression to liver cancer in the context of human patients and mouse models. It focuses on the role of ATX/LPA in NAFLD development and its progression to liver cancer as NAFLD has an increasing incidence which is associated with the increasing incidence of liver cancer. Bearing in mind that adipose tissue accounts for the largest amount of LPA production, many studies have implicated LPA in adipose tissue metabolism and inflammation, liver steatosis, insulin resistance, glucose intolerance and lipogenesis. At the same time, LPA and ATX play crucial roles in fibrotic diseases. Given that hepatocellular carcinoma (HCC) is usually developed on the background of liver fibrosis, therapies that both delay the progression of fibrosis and prevent its development to malignancy would be very promising. Therefore, ATX/LPA signaling appears as an attractive therapeutic target as evidenced by the fact that it is involved in both liver fibrosis progression and liver cancer development. MDPI 2019-10-23 /pmc/articles/PMC6893780/ /pubmed/31652837 http://dx.doi.org/10.3390/cancers11111626 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kaffe, Eleanna
Magkrioti, Christiana
Aidinis, Vassilis
Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
title Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
title_full Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
title_fullStr Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
title_full_unstemmed Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
title_short Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
title_sort deregulated lysophosphatidic acid metabolism and signaling in liver cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893780/
https://www.ncbi.nlm.nih.gov/pubmed/31652837
http://dx.doi.org/10.3390/cancers11111626
work_keys_str_mv AT kaffeeleanna deregulatedlysophosphatidicacidmetabolismandsignalinginlivercancer
AT magkriotichristiana deregulatedlysophosphatidicacidmetabolismandsignalinginlivercancer
AT aidinisvassilis deregulatedlysophosphatidicacidmetabolismandsignalinginlivercancer